Latest Prostate cancer Stories
WASHINGTON, March 26, 2013 /PRNewswire-USNewswire/ -- Quentin "Skip" Lockwood, III, President and Chief Executive Officer of ZERO - The End of Prostate Cancer has resigned his position in order to pursue a new opportunity at a family business in upstate New York. Skip lent his leadership skills to the organization for thirteen years, serving five of those as CEO. (Logo: http://photos.prnewswire.com/prnh/20130129/DC50244LOGO) "The Board would like to thank Skip for his incredible...
Recent news of high-profile lung cancer cases and deaths highlights need for more funding and better research SAN CARLOS, Calif., March 26, 2013 /PRNewswire-USNewswire/ -- The following statement was issued by Bonnie J. Addario in light of Bobbie Smith, lead singer of The Spinners, losing his battle with lung cancer last week: (Logo: http://photos.prnewswire.com/prnh/20110630/DC28681LOGO-b) "Lung cancer has been in the news a lot lately, with high-profile celebrities like Valerie...
SAN FRANCISCO, March 26, 2013 /PRNewswire/ -- New research adds to the growing body of evidence that modified citrus pectin (MCP), a natural supplement derived from the pith of citrus fruit, has a powerful effect against cancer. In a study just published in the March 2013 issue of the journal Integrative Cancer Therapies, MCP enhanced the anti-cancer effects of two botanical formulas, one for breast cancer and one for prostate cancer. The combination treatment decreased cancer cell...
EXTON, Pa., March 25, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceuticals issues, finds that, despite the 2012 launch of Medivation/Astellas Pharma's Xtandi (enzalutamide) for the treatment of docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC), surveyed oncologists report that Johnson & Johnson/Janssen Biotech/Janssen-Cilag's Zytiga continues to dominate the second-line...
$10.5 million funding for Department of Defense Lung Cancer Research Program Included Despite Threats of Sequestration WASHINGTON, March 21, 2013 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) commends the US Congress on the passage of a Continuing Resolution for the remainder of FY2013 that includes $10.5 million in funding for the Department of Defense (DOD) Lung Cancer Research Program. This would bring the total funding so far for this program, which was...
Demonstrates Weight Maintenance and Increase in Patient Appetite and Quality Of Life NEW YORK, March 21, 2013 /PRNewswire/ -- Ohr Pharmaceutical (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients,...
Experienced physician launches site to inform the public about this advanced treatment option. Oakland, CA (PRWEB) March 20, 2013 Dennis R. Hill MD announces the launch of a new website designed to inform the public about a technologically advanced and efficient form of treatment for prostate cancer hdrprostatebrachytherapy.com. Dr. Hill specializes in high dose rate brachytherapy and is one of the few physicians in the country to do so exclusively. Prostate cancer is a disease that is of...
Leading magazine downplays value of lung cancer screenings, to the detriment of advances in early detection research SAN CARLOS, Calif., March 20, 2013 /PRNewswire-USNewswire/ -- The following statement was issued by Bonnie J. Addario regarding the March cover article in Consumer Reports: The cancer tests you need--and those you don't: "I am appalled by the March 2013 Consumer Reports cover story (The cancer tests you need--and those you don't), because of the misleading and...
PCL Alverno Laboratories Introduces Oncimmune’s EarlyCDT®-Lung, a Blood Test to Aid in Risk Assessment and the Early Detection of Lung Cancer (PRWEB) March 19, 2013 PCL Alverno announced today that it has recently entered into an agreement with Oncimmune® USA LLC to offer EarlyCDT®-Lung to their extensive physician base in the Midwest. EarlyCDT-Lung is an innovative blood test that aids in the risk assessment and the early detection of lung cancer. “Oncimmune is...
The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic...
